



David Michael Asmuth, M.D.

Philosophy of Care	Dr. Asmuth's philosophy of care is based on patient autonomy and providing a proactive approach to medical therapy. He seeks to provide information to the patient in a partnership that focuses on maintaining health and limiting the long-term consequences of chronic infections, especially HIV and HCV.
Clinical Interests	<p>Dr. Asmuth has had over 25 years experience treating patients with general infectious diseases with a focused interest in HIV/AIDS and HIV/HCV coinfection. He also treats patients with HCV infection alone.</p> <p>Dr. Asmuth has conducted approximately 100 clinical trials in the treatment of HIV/AIDS, HIV/HCV coinfection, and HCV monoinfection over the last twenty-five years of clinical research. He has a special interest in translational research trials that focus on HIV pathogenesis, immune reconstitution following initiation of anti-HIV medications, and the impact of HIV infection on mucosal immunity in the gastrointestinal tract. He has recently directed attention to host-microbiome interactions in HIV enteropathy and their effects on systemic immune activation. In addition, he has written and conducted clinical trials for the development of preventive and therapeutic vaccines for HIV, immune-based therapies, and is collaborating with researchers exploring the role of stem cell approaches for the treatment of HIV.</p>
Title	Professor of Medicine
Specialty	Infectious Diseases, Internal Medicine
Department	Internal Medicine
Division	Infectious Diseases
Center/Program Affiliation	Pacific AIDS Education and Training Center
Address/Phone	CARES Clinic, 1500 21st St. Sacramento, CA 95811 Phone: 800-2-UCDAVIS
Education	M.D., Northwestern University, Chicago, Illinois, 1985 B.A., University of Notre Dame, South Bend, Indiana, 1977
Internships	University of Wisconsin Hospital and Clinics, Madison, Wisconsin, 1985-86
Residency	Primary Care/Boise Tract, University of Washington at Seattle, Seattle, Washington, 1986-88



David Michael Asmuth, M.D.

- Fellowships** Deaconess Hospital/Harvard Medical School, Boston, Massachusetts, 1989-93
University of Washington-Seattle, Boise, Idaho, 1988-89
- Board Certifications** American Board of Internal Medicine, 1988
American Board of Internal Medicine, Infectious Disease, 1992
- Professional Memberships** American College of Physicians
Infectious Diseases Society of America
International Society of Analytical Cytometry
Veterans Administration Northern California Health Care System-Associate Chief of Staff for Research and Development
- Honors and Awards** Nominated for Excellence in Teaching Award - Department of Internal Medicine - UTMB, 1999
Humanism in Medical Education Award - AAMC UTMB nominee, 1999
- Select Recent Publications** Asmuth DM, Ma Z-M, Mann S, Knight TH, Yotter T, Albanese A, Melcher GP, Troia-Cancio P, Hayes T, Miller CJ, Pollard RB. Gastrointestinal-Associated Lymphoid Tissue (GALT) Immune Reconstitution in a Randomized Clinical Trial of Raltegravir Versus NNRTI-based Regimens. *AIDS* 2012; Aug 24;26(13):1625-34
Chary A, Winters MA, Eisen R, Knight TH, Asmuth DM, Holodniy M. Quantitation of Hepatitis C Virus RNA in Peripheral Blood Mononuclear Cells from HCV-Monoinfected and HIV/HCV-Coinfected Patients. *J Med Virol.* 2012 84(3):431-437.
Maniar A, Ellis CE, Asmuth D, Pollard RB, Rutledge J. HIV Infection and Atherosclerosis: Evaluating the Drivers of Inflammation. *Eur J Prev Cardiol.* 2012. May 3.
Schunter M, Chu H, Hayes TL, McConnell D, Crawford SS, Luciw PA, Bengmark S, Asmuth DM, Brown J, Bevins CL, Shacklett BL, Critchfield JW. Randomized Pilot Trial of a Synbiotic Dietary Supplement in Chronic HIV-1 Infection. *BMC Complement Altern Med.* 2012 Jun 29;12(1):84
Hubbard JJ, Greenwell-Wild T, Yang J, Lempicki RA, Wahl SM, Asmuth DM, Murphy RL, Pollard RB, Kottlil S. Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with Pegylated interferon-alpha 2a. *J Infect Dis.* 2012;205:1443-7.
Imamichi H, Degray G, Asmuth DM, Fischl MA, Landay AL, Lederman MM, Sereti I. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. *AIDS.* 2011 Jan 14;252:159-64.
Ellis CL, Ma Z-M, Mann SK, Li C-S, Wu J, Knight TH, Yotter T, Hayes TL, Maniar AH, Troia-Cancio PV, Overman HA, Torok NJ, Albanese A, Rutledge JC, Miller CJ, Pollard RB, Asmuth DM, Molecular Characterization of Stool Microbiota in HIV-Infect Subjects by Panbacterial and Order-Level 16S Ribosomal DNA rDNA Quantification and Correlations with Immune Activation. *J*



David Michael Asmuth, M.D.

Acquir Immune Defic Syndr. 2011 575:363-370, August 15, 2011.

Asmuth DM, Murphy RL, Rosencranz SL, Lertora JJ, Kottlil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li X-D, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB. Safety, Tolerability and Mechanisms of Antiretroviral Activity of Peginterferon alfa-2a in HIV-1-Mono-infected Subjects: A Phase II Clinical Trial. J Infect Dis. Jun 1, 2010; 20111:1686-96.

Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS, Casimiro DR, Shiver JW, Robertson MN, Quirk EK, Mehrotra DV. Comparative Cell-Mediated Immunogenicity of DNA/DNA, DNA/Ad5, or Ad5/Ad5 HIV-1 Clade B gag Vaccine Prime-Boost Regimens. J Infect Dis. 2010 Jan 2011:132-41.

Asmuth DM, Goodrich J, Cooper DA, Haubrich R, Rajicic N, Hirschel B, Mayer H, Valdez H. CD4 T-Cell Restoration after 48 Weeks in the Maraviroc Treatment-experienced Trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. Aug 1, 2010;544:394-7.

© 2015 UC Regents